Cash Expected to Fund Operations through the End of 2017 Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017 PRINCETON, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical...
PRINCETON, N.J. , April 15, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products announced today that Dr....